Equities

GSK plc

GSK:LSE

GSK plc

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2,198.00
  • Today's Change18.00 / 0.83%
  • Shares traded8.48m
  • 1 Year change48.56%
  • Beta0.7262
Data delayed at least 20 minutes, as of Feb 06 2026 14:54 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy3
Outperform4
Hold13
Sell4
Strong Sell0

Share price forecast

The 20 analysts offering 12 month price targets for GSK plc have a median target of 1,840.00, with a high estimate of 2,570.00 and a low estimate of 1,455.00. The median estimate represents a -15.60% decrease from the last price of 2,180.00.
High17.9%2,570.00
Med-15.6%1,840.00
Low-33.3%1,455.00

Dividends

In 2025, GSK plc reported a dividend of 0.66 GBP, which represents a 8.20% increase over last year. The 18 analysts covering the company expect dividends of 0.70 GBP for the upcoming fiscal year, an increase of 5.45%.
Div growth (TTM)8.20%
More ▼

Earnings history & estimates

On Feb 04, 2026, GSK plc reported 4th quarter 2025 earnings of 25.50 per share. This result exceeded the 22.78 consensus of the 8 analysts covering the company and exceeded last year's 4th quarter results by 9.91%.
The next earnings announcement is expected on Apr 29, 2026.
Average growth rate+15.44%
GSK plc reported annual 2025 earnings of 172.00 per share on Feb 04, 2026.
Average growth rate+5.11%
More ▼

Revenue history & estimates

GlaxoSmithKline plc had 4th quarter 2025 revenues of 8.62bn. This bettered the 8.47bn consensus of the 9 analysts covering the company. This was 17.04% above the prior year's 4th quarter results.
Average growth rate+1.68%
GlaxoSmithKline plc had revenues for the full year 2025 of 32.67bn. This was 4.11% above the prior year's results.
Average growth rate+7.43%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.